Lee Yu-Hsiang, Huang Cheng-You
Department of Biomedical Sciences and Engineering, National Central University, Taoyuan City, Taiwan, Republic of China.
Department of Chemical and Materials Engineering, National Central University, Taoyuan City, Taiwan, Republic of China.
Int J Nanomedicine. 2025 Jan 8;20:327-342. doi: 10.2147/IJN.S505458. eCollection 2025.
Cancer treatments are still limited by various challenges, such as off-target drug delivery, posttreatment inflammation, and the hypoxic conditions in the tumor microenvironment; thus, the development of effective therapeutics remains highly desirable. Exosomes are extracellular vesicles with a size of 30-200 nm that have been widely applied as drug carriers over the last decade. In this study, melanoma-derived exosomes were used to develop a perfluorocarbon (PFC) drug nanocarriers loaded with indocyanine green (ICG) and camptothecin (CPT) (ICFESs) for targeted cancer photochemotherapy.
The ICFESs were fabricated by emulsification approach and characterized through instrumental detection. The capabilities of the ICFESs on tumor targeting, intratumoral retention, and cancer photochemotherapy were evaluated using melanoma tumor-bearing mice in association with histological studies and serum marker analyses.
ICFESs can be rapidly internalized by homologous melanoma cells, induce hyperthermia and increase the yield of singlet oxygen upon exposure to near-infrared (NIR) irradiation. After 5 min of NIR exposure and 24 h of in vitro culture, ICFESs encapsulating ≥ 10/10 μM [ICG]/[CPT] effectively killed more than 70% of the cancer cells, inducing greater mortality than that caused by a 4-fold higher dose of CPT alone. In a murine melanoma model, we demonstrated that ICFESs indeed targeted homologous tumors with prolonged intratumoral retention compared with free ICG in vivo. Moreover, tumor growth was significantly arrested by ICFESs containing 40/40 μM [ICG]/[CPT] in combination with 30 sec of NIR exposure without systemic toxicity, and the resulting tumors were approximately 15-fold smaller than those treated for 14 days with 40 μM free CPT alone.
We suggest that the aforementioned anticancer efficacy was achieved via a dual-stage mechanism, phototherapy followed by chemotherapy. Taken together, the developed ICFESs are anticipated to be highly applicable for clinical cancer treatment.
癌症治疗仍受到各种挑战的限制,如脱靶药物递送、治疗后炎症以及肿瘤微环境中的缺氧状况;因此,开发有效的治疗方法仍然非常必要。外泌体是大小为30 - 200 nm的细胞外囊泡,在过去十年中已被广泛用作药物载体。在本研究中,黑色素瘤来源的外泌体被用于开发负载吲哚菁绿(ICG)和喜树碱(CPT)的全氟碳(PFC)药物纳米载体(ICFESs),用于靶向癌症光化学疗法。
通过乳化方法制备ICFESs,并通过仪器检测对其进行表征。使用荷黑色素瘤小鼠结合组织学研究和血清标志物分析,评估ICFESs在肿瘤靶向、瘤内滞留和癌症光化学疗法方面的能力。
ICFESs可被同源黑色素瘤细胞快速内化,在近红外(NIR)照射下诱导热疗并增加单线态氧的产量。在NIR照射5分钟和体外培养24小时后,包封≥10/10 μM [ICG]/[CPT]的ICFESs有效杀死了超过70%的癌细胞,诱导的死亡率高于单独使用4倍剂量CPT所导致的死亡率。在小鼠黑色素瘤模型中,我们证明与体内游离ICG相比,ICFESs确实靶向同源肿瘤并具有延长的瘤内滞留时间。此外,含有40/40 μM [ICG]/[CPT]的ICFESs与30秒的NIR照射联合使用可显著抑制肿瘤生长且无全身毒性,所产生的肿瘤比单独用40 μM游离CPT治疗14天的肿瘤小约15倍。
我们认为上述抗癌疗效是通过光疗后化疗的双阶段机制实现的。综上所述,所开发的ICFESs有望高度适用于临床癌症治疗。